Rosuvastatin

Drugs

Volumn 62, Issue 14, 2002, Pages 2075-2085

  Carswell, Christopher I ^a   Plosker, Greg L ^a   Jarvis, Blair ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; DIGOXIN; ERYTHROMYCIN; FENOFIBRATE; FLUCONAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; NICOTINIC ACID; OMEPRAZOLE; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SULFAPHENAZOLE;

AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG TOLERANCE; DYSLIPIDEMIA; FLU LIKE SYNDROME; HEADACHE; HUMAN; MYALGIA; PAIN; PHARYNGITIS; REVIEW; SUSTAINED RELEASE PREPARATION;

EID: 0036402577     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262140-00008     Document Type: Review

References (57)

1. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association, 2002
2. McKenney JM. The cost of treating dyslipidaemia using National Cholesterol Education Program (NCEP) guidelines. PharmacoEconomics 1998; 14 Suppl. 3: 19-28
3. Amsterdam EA, Deedwania PC. A perspective on hyperlipidemia: Concepts of management in the prevention of coronary artery disease. Am J Med 1998 Jul 6; 105 Suppl. 1 A: 69-74
4. Shepherd J, Cobbe S, Ford I. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995 November 16; 333 (20): 1301-7
5. Scandinavian Simvastatin Survival Study group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994 November 19; 344: 1383-9
6. Assman G, Cullen P, Jossa F, et al. Coronary heart disease: Reducing the risk: The scientific background to primary and secondary prevention of coronary heart disease: A worldwide view. Arterioscler Thromb Vasc Biol 1999 Aug; 19: 1819-24
7. Wood D, De BG, Faergeman O, et al. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of the European and other Societies on Coronary Prevention. Atherosclerosis 1998 Oct; 140: 199-270
8. Expert Panel on Detection E and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program. JAMA 2001 May 16; 285 (19): 2486-97
9. Chong PH, Bachenheimer BS. Current,new and future treatments in dyslipidaemia and atherosclerosis. Drugs 2000 July; 60: 55-93
10. Hatch GM. Rosuvastatin. Current Opinion in Cardiovascular, Pulmonary and Renal Investigational Drugs 2000; 2 (3): 270-3
11. Graul A, Castaner J. ZD-4522. Hypolipidemic, HMG-CoA reductase inhibitor. Drugs Future 1999; 24 (5): 511-3
12. The LIPID study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 November 5; 339 (19): 1349-57
13. Sacks F, Pfeffer M, Moye L. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996 October 3; 335 (14): 1001-9
14. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999 Aug 12; 341 (7): 498-511
15. McTaggart F, Buckett L, Davidson R. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitor. Am J Cardiol 2001 Mar 8; 87 Suppl. 5a: 28B-32B
16. Watanabe M, Koike H, Ishiba T, et al. Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem 1997; 5 (2): 437-44
17. Cameron NE, Smith GJ, McTaggart F, et al. Effects of treatment with the statin, ZD4522, on peripheral nerve function and perfusion in diabetic rats [abstract]. Diabetologia 2000 Aug; 43 Suppl. 1: 50
18. Prass R, Caslake M, Packard CJ, et al. Rosuvastatin enhances lipid fluidity in atherogenic apoB-containing lipoproteins. [poster] Presented at the European Atherosclerosis Society, 73rd EAS Congress, Slazburg, Austria, 2002 7-10 July
19. Brown CDA, Windass A, Bleasby K, et al. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C. Poster and abstract presented at the European Atherosclerosis Society, 72nd EAS Congress; 2001 May 20-23; Glasgow, UK
20. Stalker T, Lefer A, Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: The role of mevalonic acid. Br J Pharmacol 2001; 133: 406-12
21. Warwick MJ, Dane AL, Raza A, et al. Pharmacokinetic and safety profile for the new HMG-CoA reductase inhibitor ZD4522 (single and multiple doses) [abstract]. Can J Cardiol 2000 Sep; 16 Suppl. F: 196F
22. Martin PD, Dane AL, Nwose D, et al. Effects of age and gender on the pharmacokinetics of rosuvastatin: A new HMG-CoA reductase inhibitor. Clin Pharmacol Ther 2001 Feb; 69 Supp.: P56
23. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamics effects and pharmacokinetics of new HMG-CoA reductase inhibitor ZD4522 after am and pm administration in healthy subjects [abstract]. J Clin Pharmacol 2000 Sep; 40: 1056
24. Martin PD, Dane AL, Schneck DW, et al. Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects [abstract]. J Clin Pharmacol 2000 Sep; 40: 1056
25. McCormick AD, McKillop D, Butters CJ, et al. ZD4522-an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems [abstract]. J Clin Pharmacol 2000 Sep; 40: 1055
26. Simonson SG, Martin PD, Mitchell PD, et al. Pharmacokinetics and pharmacodynamics of rosuvastatin in hepatically impaired subjects. Clin Pharmacol Ther 2001 Feb; 69 Suppl.): 86
27. Kemp J, Martin P, Olise MD. Coadministration of rosuvastatin does not alter the pharmacokinetics of digoxin. Pharmacotherapy 2001 Oct; 21 (10): 1255
28. Cooper KJ, Martin FD, Dane AL, et al. Erythromycin has no clinically relevant effect on the pharmacokinetics of rosuvastatin. Pharmacol Toxicol 2001; 89 Suppl. 1: 75 Abstract no. 286
29. Martin PD, Cooper KJ, Dane AL, et al. Ketoconazole has no clinically relevant: Effect on the pharmacokinetics of rosuvastatin. Pharmacol Toxicol 2001; 89 Suppl. 1: Abstract no. 286
30. Cooper KJ, Martin PD, Dane AL, et al. Fluconazole has no clinically relevant effect on the pharmacokinetics of rosuvastatin. Pharmacol Toxicol 2001; 89 (Suppl. 1): Abstract no. 288
31. Martin PD, Cooper KJ, Dane AL, et al. Itraconazole produces modest increases in rosuvastatin plasma concentrations. Pharmacol Toxicol 2001; 89 (Suppl. 1): Abstract no. 297
32. Martin PD, Dane A, Nwose OM, et al. Lack of pharmacokinetic interaction between rosuvastatin and fenofibrate in healthy volunteers. Pharmacol Toxicol 2001; 89 Suppl. 1: Abstract no. 298
33. Olsson A, Southworth H, Wilpshaar JW, et al. Long-term efficacy and safety of rosuvastatin: results of a 52-week comparator trial versus atorvastatin. Eur Heart J 2001 Sep; 22 Suppl.: M10333
34. Davidson M, Ma P, Stein E, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002; 89: 268-75
35. Knopp R, Ballantyne C. McPherson R, et al. Comparing rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia. Eur Heart J 2002 Aug; 4: 19
36. Brown WV, Chitra RR, Zedler BK, et al. Long-term efficacy and safety of rosuvastatin: Results of a 52-week comparator-controlled trial versus pravastatin and simvastatin. Eur Heart J 2001 Sep; 22 Suppl.: M10333
37. Paoletti R, Fahmy M, Mahla G, et al. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: A randomized, double-blind study. J Cardiovasc Risk 2001; 8: 383-90
38. Hunninghake DB, Chitra RR, Simonson G, et al. Treatment of hypertriglyceridemic patients with rosuvastatin. Diabetes 2001 Jun; 50 Suppl.2: A143
39. Durrington P, Hamarin A, Tuomilehto J, et al. Rosuvastatin alone and in combination with fenofibrate in hyperlipidaemic patients with type 2 diabetes. Diabetologia 2001; 44 Suppl. 1: A165
40. Morgan JM, Cressman MD, Hutchinson HG, et al. Beneficial effects of combination therapy with rosuvastatin and extended-release niacin in patients with a mixed dyslipidemia [poster]. XIV International Symposium on Drugs Affecting Lipid Metabolism 2001 Sep 9-12 New York
41. Hassman D, Berlin NJ, Ballantyne CM, et al. Rosuvastatin lowers non-high-density lipoprotein cholesterol and apolipoprotein B values compared with atorvastatin, simvastatin and pravastatin. Circulation 2002; 105 (14): Abstract
42. Marais D, Raal F, Stein E, et al. Effect of rosuvastatin on LDL-cholesterol, mevalonic acid, and other lipid measurements in patients with homozygous familial hypercholesterolaemia. Poster and abstract presented at the 73rd European Atherosclerosis Society Congress July 2002 7-10
43. Stein E, Strutt KL, Miller E. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2001 Feb; 37 Suppl. A: 292
44. Shepherd J, Packard C, Smith K, et al. Evaluation of Rosuvastatin in the Treatment of Hypercholesterolaemia in Postmenopausal Women. Poster and abstract presented at the 73rd European Atherosclerosis Society Congress 2002 July 7-10
45. Saito Y, Goto Y, Dane A, et al. Randomised, double-blind, placebo-controlled, dose-ranging study of Rosuvastatin in Japanese Hypercholesterolaemic subjects. Poster and abstract presented at the 73rd European Atherosclerosis Society Congress July 7-10 2002
46. Wiklund O, Davidson M, Chitra R, et al. Rosuvastatin is more effective than atorvastatin in modifying lipid profiles and achieving National Cholesterol Education Program Adult Treatment Panel III LDL-cholesterol goals. Presented as a poster and abstract at the 73rd European Atherosclerosis Society Congress; 2002 July 7-10; Salzburg, Austria
47. Strutt K, Caplan R, Hutchinson H, et al. More Western Hypercholesterolaemic patients achieve Japanese Atherosclerosis Society LDL-C targets with rosuvastatin therapy than with atorvastatin therapy. Poster and abstract presented at the 73rd European Atherosclerosis Society Congress; 2002 July 7-10; Salzburg, Austria
48. Istad H, Ose L, Stender S, et al. Achievement of the Joint European Societies LDL-cholesterol Goal by hypercholesterolaemic patients receiving rosuvastatin or atorvastatin. Poster and abstract presented at the 73rd European Atherosclerosis Congress; 2002 July 7-10; Salzburg, Austria
49. Hamilton-Craig I, Schaefer E, Farnier M, et al. Rosvastatin produces significantly greater reductions in low-density lipoprotein cholesterol and more patients achieve treatment goals compared with simvastatin [abstract]. J Am Coll Cardiol 2002 May 1; 39 (9 Suppl. B): 146B
50. Barter P, Shepherd J, Brown WV, et al. Rosuvastatin significantly improves lipid parameters and ability to achieve low-density lipoprotein cholesterol goals compared with pravastatin. J Am Coll Cardiol 2002 May 1; 39 (9 Suppl. B): 142B
51. Paoletti R, Bertolini S, Pisciotta L, et al. Achievement of the Joint European Societies LDL-cholesterol goal by hypercholesterolaemic patients receiving rosuvastatin, pravastatin or simvastatin. Poster and abstract presented at the 73rd European Atherosclerosis Society Congress; 2002 July 7-10; Salzburg, Austria
52. Olsson A, Pears J, Mckellar J, et al. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001 Sep 1; 88: 504-8
53. Expert Panel on Detection E and T of high blood cholesterol in A. Summary of the second report of the National Cholesterol Education Program NCEP expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993: 269: 3015-23
54. Strutt K, Dane A, Blasetto J. More Western hypercholesterolaemic patients achieve Japan Atherosclerosis Society LDL-C targets with rosuvastatin therapy than with pravastatin or simvastatin therapy. Poster presented at the 73rd European Atherosclerosis Society Congress; 2002 July 7-10; Salzburg, Austria
55. Shepherd J, Carbarns I, Harris S, et al. Safety of Rosuvastatin in patients developing LDL-C <2.07 mmol/L and <1.29 mmol/L in clinical trials. Poster presented at the 73rd European Atherosclerosis Society Congress; 2002 July 7-10; Salzburg, Austria
56. Shepherd J, Hunninghake D, Harris S, et al. A review of the safety profile of rosuvastatin in an international phase II/III clinical trial programme. Int J Clin Pract 2001; (Suppl. 124)
57. AstraZeneca. AstraZeneca update on Crestor [Online]. Available from URL:http://wwwastrazenecacom [Accessed 2002 Aug 15]